As Fred Hassan was ushered off-stage, about 13 years ago — it became clear that Kenilworth would never be bought by another major pharma player — as a whole. [It was over two million square feet, after all.] So the proposal was to split it up and create “R&D incubators” — but that never got off the ground. So “New Merck” moved back in. Then last year, HQ was moved… W A Y back — to Rahway, under Mr. Davis. [That’s a 1960s throwback move, BTW.]

And so, once again, Onyx and another firm are being tasked with trying to turn Kenilworth into small incubators of R&D, leased to independents… over time. Same old. . . same old. Here’s the story — from 13 years ago, now — from first time around, at legacy Schering-Plough:

…Anonymous said…

The way it was explained to us (1 of the 580 being let go) They are closing every building on site, except one research building that they are dumping the $120 million into, and selling off the rest of the space.

The size of the site will be about 1/4 what it is now. Fred’s old office building will be gone by 2013; a few other buildings are already vacant. That nj.com story makes this seem like a good thing.

January 7, 2011 3:06 PM….

I’d expect about the same level of… non-success, this time around — in all honesty. The real estate needs of big companies are smaller, now — post COVID, and pro- tele-work. Smile — happy V-day, to all. . . .

नमस्ते